相关实验视频

Updated: Sep 18, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

雷塔鲁提德-在肥胖药物治疗中的游戏改变者

Vasiliki Katsi¹, Georgios Koutsopoulos¹, Christos Fragoulis¹

¹1st Cardiology Clinic, National & Kapodistrian University of Athens, 11527 Athens, Greece.

|June 26, 2025

概括

雷塔胺是一种三重受体激动剂,可显著降低体重并改善肥胖和2型糖尿病的血糖控制. 这种新疗法对代谢健康有前途,目前正在进行试验,评估长期结果.

科学领域:

药理学药理学是指药理学的学科.
代谢疾病代谢疾病
内分泌学在内分泌学.

背景情况:

肥胖和2型糖尿病 (T2DM) 是全球重大健康挑战.
现有的药物疗法在有效性和患者坚持治疗方面存在局限性.
新的治疗点对于管理这些复杂的代谢状况至关重要.

研究的目的:

审查三重受体agonist的retatrutide的机制,疗效和安全性.
综合从临床前和临床研究中对肥胖和T2DM治疗的雷达胺的发现.
突出雷达胺作为下一代治疗的潜力.

主要方法:

对临床前动物研究的综述,评估了雷达对胃排空,食物摄入量和体重的影响.
分析了I期和II期临床试验数据,这些数据是关于雷达对体重,糖化血红蛋白 (HbA1c) 和代谢参数的影响.
综合安全数据,包括不良影响和正在进行的III期试验设计 (例如TRIUMPH研究).

主要成果:

雷塔鲁提德证明了葡萄糖类-1 (GLP-1),依赖葡萄糖的胰岛素型多 (GIP) 和葡萄糖受体的强烈激活.
临床前研究表明,与其他基于烯的疗法相比,减肥效果更好.
临床试验表明剂量依赖的减肥,改善HbA1c,对肝硬化和糖尿病病有好处.

结论:

雷塔胺代表了肥胖和T2DM的药物治疗中的重大进步.
该药物表现出有前途的安全性和有效性,主要是与剂量相关的胃肠道副作用.
需要对减肥的长期结果,成本效益和质量进行进一步的研究.

关键词:

不同的形物是不一样的.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖逆转的时间逆转的时间 2型糖尿病是什么?

更多相关视频

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

相关概念视频

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...